Table of Contents

• What is the FDA Proposing?
• 503A vs. 503B: What Is the Difference?
• Will Compounded Semaglutide Be Completely Banned?
• Why Is the FDA Making This Move?
• Is Compounded Semaglutide Still Safe to Use?
• What Are the Alternatives?
• What Should You Do If You Are Currently on Compounded Semaglutide?
• What This Means for Profusions Patients

TL;DR

On April 30, 2026, the FDA proposed removing semaglutide, tirzepatide, and liraglutide from the 503B bulk drug substances list — the regulatory framework that allowed large-scale compounding pharmacies to manufacture and distribute these GLP-1 medications at lower cost. The public comment window closes June 29, 2026. Once finalized, this proposal effectively ends large-scale compounded GLP-1 distribution through outsourcing facilities. Patient-specific compounding through 503A pharmacies may still continue under narrow circumstances. If you are currently on compounded semaglutide or tirzepatide, this is the time to speak with your provider about your options.

What is the FDA Proposing?

On April 30, 2026, the U.S. Food and Drug Administration announced a proposal to exclude three GLP-1 medications — semaglutide (the active ingredient in Wegovy and Ozempic), tirzepatide (the active ingredient in Zepbound and Mounjaro), and liraglutide — from the 503B Bulk Drug Substances List.

The 503B list is the regulatory mechanism that authorized large-scale outsourcing facilities to compound these drugs in bulk and distribute them to patients nationwide through telehealth providers. The FDA found no qualifying clinical need for this level of compounding now that branded GLP-1 medications are back in stable supply.

"When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need," FDA Commissioner Marty Makary stated in the agency's announcement. Source: Orrick Legal Analysis

The public comment period closes June 29, 2026. After that, the FDA will review comments and finalize the rule, which will effectively close the door on bulk GLP-1 compounding at scale.

503A vs. 503B: What Is the Difference?

Understanding these two designations is essential to knowing how this affects you.

503B (Outsourcing Facilities)

503B facilities are large-scale compounding operations that produce medications in bulk and distribute them to patients across multiple states — often through telehealth platforms. These facilities do not need an individual patient prescription before manufacturing. The FDA's proposal targets 503B compounding, which is where the majority of telehealth-distributed compounded semaglutide came from.

503A (Traditional Compounding Pharmacies)

503A pharmacies operate under a different model. They compound medications for individual patients based on a specific prescription from a licensed provider. Under current FDA guidance, 503A compounding of semaglutide may still be permitted in a narrow set of circumstances — specifically when a patient has a documented medical need that a commercially available product cannot meet (such as an allergy to an inactive ingredient). Source: FDA.gov

The short version: Mass-produced compounded GLP-1s are on their way out. Individualized, provider-prescribed compounding under narrow criteria may continue.

Will Compounded Semaglutide Be Completely Banned?

Not entirely — but the practical reality is close to it for most patients.

503B bulk compounding, which supplied the majority of low-cost compounded semaglutide through telehealth platforms, faces a near-complete shutdown under this proposal. 503A compounding by individual patient-specific pharmacies can technically continue, but only under strict conditions:

• The patient has a valid individual prescription from a licensed provider
• The compounded product is not essentially a copy of a commercially available product
• There is a documented, clinically justified reason the branded product cannot be used

For the vast majority of patients who used compounded semaglutide primarily for cost savings, these exceptions will not apply. Source: Medical News Today

Why Is the FDA Making This Move?

Three core reasons are driving this decision:

1. The shortage justification is gone. GLP-1 shortage designations for both semaglutide and tirzepatide were resolved in 2025. The original rationale for allowing bulk compounding — that patients could not access the branded drugs — no longer holds.

2. Safety concerns are real. The FDA documented over 100 hospitalizations and at least 10 deaths linked to compounded semaglutide, primarily from dosing errors. The lack of standardization in bulk compounding creates patient safety risks that the agency can no longer overlook. The FDA also sent 30 warning letters to telehealth companies for falsely marketing compounded GLP-1s that were not FDA-approved.

3. Pharmaceutical partnerships are shifting. Major telehealth companies including Hims & Hers and Ro have already signed distribution partnerships directly with Novo Nordisk and Eli Lilly, transitioning their weight loss businesses to branded GLP-1 access. The regulatory landscape is following market behavior, not leading it.

Is Compounded Semaglutide Still Safe to Use?

Compounded medications are not FDA-approved finished drug products. While many patients have had positive experiences, the safety profile of compounded GLP-1s is inconsistent — dosing errors, contamination risks, and lack of quality control at some facilities have led to documented adverse events.

If you are currently taking compounded semaglutide and experiencing side effects or have concerns, speak with a licensed provider immediately. Do not stop or adjust your dose without medical guidance.

What Are the Alternatives?

The shift toward branded GLP-1s is significant, but access has improved considerably.

Manufacturer savings programs through NovoCare (Novo Nordisk) and LillyDirect (Eli Lilly) have dramatically reduced out-of-pocket costs for eligible patients. FSA and HSA dollars are also applicable in many cases.

Beyond GLP-1s, a comprehensive weight loss plan may also include:

• Sermorelin — a growth hormone-releasing peptide that supports metabolic function and body composition
• GLP-1 Microdose protocols — lower-dose GLP-1 programs designed for patients who experienced significant side effects at standard doses
• Oral weight loss medications — non-GLP-1 prescription options for patients who prefer non-injectable treatment
• NAD+ therapy — supports cellular energy and metabolic health as part of a longevity-focused weight management protocol

What Should You Do If You Are Currently on Compounded Semaglutide?

Act now — do not wait until June 29. Here are your immediate steps:

1. Schedule a provider consultation. Review your current protocol, your health goals, and what the transition to a branded GLP-1 or alternative program looks like for your specific situation.
2. Ask about manufacturer savings programs. Both Novo Nordisk and Eli Lilly have self-pay pricing programs that can bring branded costs closer to what you were paying for compounded versions.
3. Do not abruptly stop your medication. GLP-1 medications involve dose titration — stopping suddenly without a transition plan can cause rebound weight gain and metabolic disruption. Always do this with provider guidance.
4. Explore your full treatment options. The shift away from compounded GLP-1s is also an opportunity to reassess your entire approach to metabolic health — hormones, peptides, energy, and body composition all play a role.

What This Means for Profusions Patients

At Profusions Health & Wellness, your treatment has always been about more than one medication. Our licensed providers work with you across a full spectrum of evidence-based therapies — GLP-1 weight loss programs, hormone optimization, peptide protocols, and longevity treatments — all through telehealth, all 50 states, no insurance required.

As the compounded GLP-1 landscape shifts, we are prepared to guide every patient through this transition with the same personalized care that has defined our approach from day one. Whether that means transitioning to a branded GLP-1 program, exploring an oral weight loss alternative, or building a multi-modal protocol around your specific health goals — we are ready to build that plan with you.

Same-day provider visits. No insurance gatekeeping. Real care, real results.

Start your consultation today →

This article is for informational purposes only and does not constitute medical advice. All treatment decisions should be made in consultation with a licensed healthcare provider. Prescription medications require a valid provider-patient relationship and medical evaluation.

Sources: FDA.gov | Orrick LLP | Pharmacy Times | Medical News Today | GoodRx